San Francisco Bay Area biotech stories.
Monday, October 10, 2011
Dynavax: Hepatitis vaccine does well in subpopulations
Dynavax Technologies Corp. said its Heplisav vaccine for hepatitis B did well in a Phase III test in so-called “hypo-responsive” groups of people, meaning men, obese people and smokers.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)